ERNA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Ernexa Therapeutics Inc (ERNA.O) is -0.01, compared to its 5-year average forward P/E of -3.18. For a more detailed relative valuation and DCF analysis to assess Ernexa Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.18

Current PE

-0.01

Overvalued PE

3.53

Undervalued PE

-9.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 463.67% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 463.67% over the last month.

Sold

Bought

ERNA News & Events

Events Timeline

No data

News

9.5

01-07Benzinga

Penguin Solutions Reports Q1 Earnings of $0.49, Shares Up 5.3%

9.0

01-06Globenewswire

Ernexa Therapeutics Targets 2026 for First-in-Human Ovarian Cancer Trial

1.0

2025-11-11Newsfilter

Ernexa Therapeutics to Showcase at Oxford Global's Cell 2025 Event

People Also Watch

Frequently Asked Questions

What is Ernexa Therapeutics Inc (ERNA) stock price today?

The current price of ERNA is 1.31 USD — it has decreased -5.76 % in the last trading day.

What is Ernexa Therapeutics Inc (ERNA)'s business?

Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

What is the price predicton of ERNA Stock?

Wall Street analysts forecast ERNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERNA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Ernexa Therapeutics Inc (ERNA)'s revenue for the last quarter?

Ernexa Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Ernexa Therapeutics Inc (ERNA)'s earnings per share (EPS) for the last quarter?

Ernexa Therapeutics Inc. EPS for the last quarter amounts to -0.15 USD, decreased -99.80 % YoY.

What changes have occurred in the market's expectations for Ernexa Therapeutics Inc (ERNA)'s fundamentals?

The market is revising No Change the revenue expectations for ERNA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 1.16%.

How many employees does Ernexa Therapeutics Inc (ERNA). have?

Ernexa Therapeutics Inc (ERNA) has 6 emplpoyees as of January 10 2026.

What is Ernexa Therapeutics Inc (ERNA) market cap?

Today ERNA has the market capitalization of 10.28M USD.